主页 > 医学动态 >
【medical-news】口服布地奈德可用于结肠炎的维持
By David Douglas
NEW YORK (Reuters Health) Jan 13 - The corticosteroid budesonide yields good long-term results in patients with collagenous colitis, Danish researchers report in the January issue of Gut.
"The study confirms our previous findings... that oral budesonide is effective in treatment of patients with collagenous colitis," lead investigator Dr. Ole K. Bonderup told Reuters Health. "In this study it was also shown that budesonide is effective in maintenance treatment of the disease."
Dr. Bonderup, of Randers Regional Hospital, and colleagues studied 34 patients who were in remission after 6 weeks of open-label budesonide induction therapy. The patients were randomized either to continue with budesonide at 6 mg per day or to receive placebo.
After 24 weeks, 13 of the 17 budesonide patients (76.5%) were in remission compared to only 2 of the 17 placebo patients (12%). The median time to relapse after stopping treatment was about 38 days in both the patients who switched to placebo and in the active treatment group. Treatment was well tolerated and most adverse events were mild and transient.
Dr. Bonderup admitted that "the risk of relapse is not reduced after discontinuation of long-term treatment."
"For patients with severe collagenous colitis," he concluded, "budesonide can be recommended as an effective treatment option."
Gut 2009;58:68-72.
http://www.medscape.com/viewarticle/586759 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领。 Budesonide Effective for Colitis Maintenance Therapy
布地奈德对结肠炎维持治疗效果显著
By David Douglas
NEW YORK (Reuters Health) Jan 13 - The corticosteroid budesonide yields good long-term results in patients with collagenous colitis, Danish researchers report in the January issue of Gut.
纽约（路透社健康新闻）1月13号-皮质类固醇药物布地奈德对胶原性结肠炎患者的长期疗效显著，丹麦研究者在《Gut》一月刊上报道了这一结果。
"The study confirms our previous findings... that oral budesonide is effective in treatment of patients with collagenous colitis," lead investigator Dr. Ole K. Bonderup told Reuters Health. "In this study it was also shown that budesonide is effective in maintenance treatment of the disease."
“这项研究证实了我们之前的发现……口服布地奈德治疗胶原性结肠炎患者是有效的，”首席研究者Ole K. Bonderup博士向路透社健康新闻表示，“这项研究还显示，布地奈德对这种疾病的维持治疗是有效的。”
Dr. Bonderup, of Randers Regional Hospital, and colleagues studied 34 patients who were in remission after 6 weeks of open-label budesonide induction therapy. The patients were randomized either to continue with budesonide at 6 mg per day or to receive placebo.
兰德地区医院的Bonderup博士和他的同事们研究了34名患者，后者在6周开放标记的布地奈德诱导治疗后病情缓解。之后，患者随机分为两组，一组继续接受每日6mg的布地奈德，另一组接受安慰剂。
After 24 weeks, 13 of the 17 budesonide patients (76.5%) were in remission compared to only 2 of the 17 placebo patients (12%). The median time to relapse after stopping treatment was about 38 days in both the patients who switched to placebo and in the active treatment group. Treatment was well tolerated and most adverse events were mild and transient.
24周后，17名布地奈德治疗的患者中13名（76.5%）仍处于缓解期，与之相比，安慰剂组仅有2人缓解（12%）。包括改服安慰剂和主动治疗组的所有患者在内，在停止治疗后中位复发时间为38天。治疗得到了很好的耐受，大部分副作用微弱且呈一过性。
Dr. Bonderup admitted that "the risk of relapse is not reduced after discontinuation of long-term treatment."
Bonderup博士承认“长期治疗后停药的复发风险并未降低”。
"For patients with severe collagenous colitis," he concluded, "budesonide can be recommended as an effective treatment option."
“对严重的胶原性结肠炎患者，”他总结说，“布地奈德可以作为一种有效的治疗选择推荐给他们。”
布地奈德对结肠炎维持治疗效果显著
纽约（路透社健康新闻）1月13号-皮质类固醇药物布地奈德对胶原性结肠炎患者的长期疗效显著，丹麦研究者在《Gut》一月刊上报道了这一结果。
“这项研究证实了我们之前的发现……口服布地奈德治疗胶原性结肠炎患者是有效的，”首席研究者Ole K. Bonderup博士向路透社健康新闻表示，“这项研究还显示，布地奈德对这种疾病的维持治疗是有效的。”
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-01 14:35
医学,生命科学网